AngioDynamics raises FY25 adjusted EBITDA view to $1M-$3M from ($2.5M)-$0

The company now expects adjusted EBITDA in the range of $1M-$3M, an increase from the previous guidance of a loss of ($2.5M)-$0. The updated guidance compares to a pro forma adjusted EBITDA loss of $3.2M in fiscal 2024. The company now expects Med Tech net sales to grow in the range of 12%-15%, an increase from 10%-12%. The company now expects Med Device net sales to be flat, a decrease from 1%-3%. The company continues to expect gross margin to be approximately 52%-53%.